HIV's Brain Sanctuary: Integrin Blockade Backfires, Exposing Gaps in CNS Viral Control

The UC Davis-led macaque study reveals that HIV (modeled via SIV) establishes permanent CNS residency by exploiting helper T cells, which cross the blood-brain barrier independently of alpha-4 integrin, while the same blockade selectively depletes killer T cells needed for viral clearance. This preclinical work (animal model, not RCT; likely n<20 total based on typical primate designs, no reported conflicts) shows inflammation-reducing therapies like natalizumab analogs increase brain viral loads by impairing cytotoxic surveillance in regions such as the hippocampus. Original coverage underplays connections to broader viral persistence patterns seen in EBV and CMV chronic infections, where similar T-cell compartmentalization failures drive neurocognitive decline. Related human observational data (e.g., from the CHARTER cohort, n>1500) link non-CNS-penetrant ART to accelerated brain aging, while a 2022 review in Nature Reviews Neurology (synthesizing autopsy and CSF studies) confirms reservoirs evade standard antivirals. No peer-reviewed human trials test integrin modulation in HIV, highlighting risks of extrapolating MS therapies without addressing helper T-cell migration. This gap demands CNS-targeted agents over systemic anti-inflammatories.